Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 December 2020 | Story André Damons | Photo Supplied
The KAT Walk mini (Omni Directional Treadmill) used to reduce and eliminate cybersickness.

An officer at the School of Nursing Simulation Laboratory of the University of the Free State (UFS) is aiming to cure or minimise cybersickness in nursing students with a popular virtual reality gaming tool.

Bennie Botha, who is acting as head of the Information, Communication and Simulation Technology at the School of Nursing Simulation Laboratory, developed a virtual environment in which nursing students use immersive virtual reality to perform a simulation scenario. This is part of his master’s degree in Computer Science and Informatics under the supervision of Dr Lizette de Wet and co-supervisor Prof Yvonne Botma.

Botha received his master’s degree with distinction during the UFS virtual graduation in October.

Cybersickness

Botha had found that some people experience cybersickness (almost like motion sickness), which is a significant issue and difficult to address. This he would now try to address with a virtual reality gaming tool – the KAT Walk mini.

According to Botha this technology has never been attempted for health-care education and is mostly used in military and pilot training and is very popular as a gaming platform for hardcore virtual reality gamers.

“To test and provide a possible solution I am going to incorporate the KAT Walk mini (Omni Directional Treadmill – almost like the Ready Player One concept) into which students are strapped and they can physically walk and turn around without the need for large open spaces.

“With this I will try and determine whether it decreases or even eliminates cybersickness due to sensory mismatch while using immersive virtual reality. I wanted to provide possible evidence of what causes cybersickness and want to enable virtual reality as an educational tool, not just for gaming. I think immersive virtual reality has a bright future if the kinks (of which the biggest is cybersickness) can be minimised,” says Botha.

Getting funding

He successfully applied for funding in 2020 and received R150 000.

“I must say I was surprised when I got the approval letter. I thought that due to the economic status it would not go through, but I was really glad when I got the approval as this is my dream and I love working with virtual reality for health care. The grant has made my dream come true, especially considering that this sounds more like something from science fiction,” says Botha.

The project started in November 2017 when Botha first conceptualised the idea and took it to Dr De Wet. He then started it as a masters’ project in 2018 and completed it at the end of 2019.

An equal opportunity for students

Botha says immersive virtual reality gives students more time and a more accessible platform where they can practise their skills as it is easy to use and easy to set up compared to other modalities of simulation. But the biggest task is developing a usable virtual environment that gives students more time to practise and increase their theory and practical integration which is key to providing highly skilled health-care professionals.

“By seeking and possibly implementing the new research, I aim to provide students an equal opportunity to partake in immersive virtual reality simulation as it currently excludes people who are prone to high levels of cybersickness. This means they cannot benefit from the same opportunities as other students do.

“I believe it can help all nursing students in SA and Africa as it is much more cost-effective than high-technology manikins and is easier to set up and access with much less manual input required to make it work (apart from the initial development.).”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept